Recombinant Humanised Igg1 Kappa Anti-Cldn1 Monoclonal Antibody Ale.F02
Fibrotic Liver Disease
Explore 26 assets in Fibrotic Liver Disease →Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
Alentis Therapeutics AG
Modality
monoclonal_antibody
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05939947CT.gov A Clinical Trial of ALE.F02 in Patients With Advanced Liver Fibrosis and/or With Mild Cirrhosis | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Fibrotic Liver Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Recombinant Humanised Igg1 Kappa Anti-Cldn1 Monoclonal Antibody Ale.F02 (this asset) | Alentis Therapeutics AG | P1 | CC · 47 |
| Entecavir | Tanta University | P4 | BB |
| Peg-Intron | Beth Israel Deaconess Medical Center | P4 | BB |
| Colchicinum | Zagazig University | P4 | BB |
| Peg-Ifn | Beijing Friendship Hospital | P4 | BB |
| Ribavirin | ANRS, Emerging Infectious Diseases | P3 | BB |
| A Therapeutic Pegylated Fibroblast Growth Factor 21 Agonist/Mimetic Which Restores Leptin Responsiveness | Bristol-Myers Squibb | P2 | BB |
| Hydronidone | Beijing Continent Pharmaceutical Co, Ltd. | P3 | BB |
| Losartan | Hospital Clinic of Barcelona | P4 | BB |
+42 more in the Fibrotic Liver Disease cohort
Other indications for Recombinant Humanised Igg1 Kappa Anti-Cldn1 Monoclonal Antibody Ale.F02
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cirrhosis Of Liver | — | P1 | CC · 42 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Recombinant Humanised Igg1 Kappa Anti-Cldn1 Monoclonal Antibody Ale.F02 in Fibrotic Liver Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/recombinant-humanised-igg1-kappa-anti-cldn1-monoclonal-antibody-alef02-fibrotic-liver-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →